Palantir delivered the highest revenue growth rate in its history as a public company — 70% YoY — and the stock sold off 12% over the following week. RSI hit 12.8 (confirmed Feb 3). US commercial revenue grew 137% YoY. Rule of 40 reached 127%, up from 81% a year ago. The market's reaction: oversold technical readings typically reserved for companies with broken fundamentals.
Nothing here is broken. The question is whether 344x forward P/E can coexist with accelerating growth, or whether gravity reasserts itself regardless of execution.
The Acceleration That Surprised No One (Except the Street)
US commercial isn't plateauing — it's reaccelerating. 93% → 121% → 137% sequential YoY growth rates across Q2, Q3, Q4. This is the land-and-expand model working at Fortune 500 scale:
- Lear Corporation: 100 users → 16,000 users post-AIP deployment (160x expansion)
- Unnamed utility: $7M → $31M annual contract value in one year (4.4x)
- Healthcare provider: $96M deal, largest commercial win to date
- Engineering services: $80M deal closed after fall demos
Management called it "manic demand." CFO David Glazer reported $4.3B in Q4 TCV bookings, up 138% YoY — the highest ever. Top 20 customer spend increased 45% YoY to $94M per customer. These aren't pilots. These are enterprise commitments at scale.
Government revenue ($730M, +60% YoY) continues to perform. The Navy awarded a $448M contract for Maven, now deployed across all combatant commands. Maven isn't a demo anymore — it's infrastructure. Defense revenue provides stable high-margin recurring cash flow while commercial rewrites the growth narrative.
The Valuation Problem
Here's the math the market is choking on:
| Ticker | P/E | Growth | PEG | Rule of 40 |
|---|---|---|---|---|
| PLTR | 344x | 70% | 4.9 | 127% |
| DDOG | 416x | ≈25% | 16.7 | ≈40% |
| SNOW | N/A | ≈25% | N/A | ≈35% |
| CRWD | N/A | ≈30% | N/A | ≈50% |
Palantir trades at 0.83x Datadog's P/E despite 2.8x the growth rate. Its Rule of 40 is 3.2x DDOG, 3.6x SNOW. On a PEG basis (4.9 vs DDOG's 16.7), Palantir is cheaper relative to growth.
But 344x P/E is still 344x P/E. The comp table shows Palantir isn't expensive relative to peers — it shows the entire AI application layer is trading at nosebleed multiples. When the risk-off trade hits (DeepSeek headlines, multiple compression fears), high-beta AI names get sold first. PLTR beta is 1.69. The selloff wasn't company-specific — it was sector rotation out of expensive AI exposure.
Factor Check: Is This a PLTR Dislocation or AI Sector Selloff?
YTD performance through Feb 3:
- PLTR: -12.0% (1M), RSI 12.8
- SNOW: -12.0% (1M), RSI 25.5
- DDOG: -3.4% (1M), RSI 52.5
- CRWD: -3.9% (1M), RSI 36.0
PLTR and SNOW moved in lockstep (-12% exactly). DDOG and CRWD held up better. This suggests sector-driven selloff with PLTR taking outsized pain due to higher beta (1.69 vs DDOG 1.29, CRWD 1.03) and valuation. Idiosyncratic variance is 53.5% — meaning roughly half the recent move is market/sector, half is PLTR-specific.
The company-specific component: Profit-taking after November highs, sell-side confusion (9 Buys, 3 Holds, 5 Sells with targets ranging $55-$180), and valuation fatigue. Options positioning is bullish (P/C ratio 0.58) but IV at 122nd percentile signals the market expects continued volatility.
The Thesis Conflict
If you believe Palantir is the enterprise AI application layer winner — the company turning LLMs into actual business process automation at scale — Q4 strongly supports that view. The growth is accelerating (not decelerating), the land-and-expand model is working (not stalling), and government provides a stable base while commercial rewrites the multiple.
If you think no company deserves 344x earnings regardless of growth trajectory, this selloff is just mean reversion.
The market priced the second view in the week following earnings. The fundamentals support the first. That gap — between RSI 12.8 technical capitulation and 137% commercial growth acceleration — is the dislocation.
RSI 12.8 doesn't persist. Either technicals bounce as buyers step in, or something fundamental breaks and it continues lower. Nothing in Q4 suggests fundamental breakage. The question is whether the multiple caps upside even when execution is flawless.
This isn't a buy-the-dip call. It's a documented case where the market (valuation compression, sector rotation) and the business (accelerating growth, expanding margins, enterprise-scale wins) are telling different stories. One of them is mispriced. The earnings date was Feb 2, 2026. The stock hasn't recovered yet.
// comments (0)